The management of menstrual suppression and uterine bleeding: A survey of current practices in the pediatric blood and marrow transplant consortium

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 553-557

  Adegite, Enitan A ^a   Goyal, Rakesh K ^b   Murray, Pamela J ^c   Marshal, Mike ^b   Sucato, Gina S ^b  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow transplantation; Gonadotropin releasing hormone; Pediatrics; Uterine hemorrhage

Indexed keywords

ETHINYLESTRADIOL; GONADORELIN AGONIST;

AMENORRHEA; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; E-MAIL; FEMALE; HEALTH SURVEY; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDIATRICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; UTERUS BLEEDING;

AMENORRHEA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CONTRACEPTIVES, ORAL, COMBINED; CROSS-SECTIONAL STUDIES; DISEASE MANAGEMENT; FEMALE; GONADOTROPIN-RELEASING HORMONE; HEALTH CARE SURVEYS; HUMANS; MENORRHAGIA; PHYSICIAN'S PRACTICE PATTERNS; UTERINE HEMORRHAGE;

EID: 84863882524     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23360     Document Type: Article

References (19)

1. Ghalie R, Porter C, Radwanska E, et al. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993; 42: 350-353.
2. Clinical Practice Guidelines. Chairman, Franklin O Smith, MD. Pediatric Blood & Marrow Transplant Consortium. September 2002. A copy can be obtained by contacting coauthor (RKG) at rakesh.goyal@chp.edu.
3. Chang BH, Edelman A, Godder K. Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant. Int J Gynaecol Obstet 2008; 100: 76-77.
4. Lee SJ, Astigarraga CC, Eapen M, et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1231-1238.
5. Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol 2007; 134: 3-8.
6. Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996; 51: 248-249.
7. Chiusolo P, Saltuari P, Sica S, et al. Lutenizing hormone-releasing hormone analogue: Leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stemm cell transplantation. Bone Marrow Transplant 1998; 21: 821-823.
8. Hägglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92: 4568-4572.
9. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
10. Gray SH, Emans SJ. Abnormal vaginal bleeding in adolescents. Pediatr Rev 2007; 28: 175-182.
11. Meirow D, Rabinovici J, Katz D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006; 107: 1634-1641.
12. Moghissi K. A clinicians guide to the use of gonadotropin-releasing hormone analogues in women. Medscape Gen Med 2000; 2: 1.
13. Sanders J, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.
14. Blumenfeld Z, Avivi I, Eckman A, et al. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008; 89: 166-173.
15. Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 2009; 91: 694-697.
16. Shenns R. Gonadal dysfunction. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer-principles & practice of oncology. Philadeplphia: J.B. Lippincott Co; 1993. p 2395-2406.
17. Oktay K, Sonmezer M. Gonadotropin-releasing hormone analogs in fertility preservation-lack of biological basis? Nat Clin Pract Endocrinol Metabol 2008; 4: 488-489.
18. Oktay K, Sonmezer M, Oktem O, et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007; 12: 1055-1066.
19. Adapted from the table on approved indications for GnRH agonists by the FDA. May 2010.